Moderna Halts CMV and Birth Defects Vaccine Programs After Trial Failures
TL;DR Summary
Moderna's experimental cytomegalovirus (CMV) vaccine failed in a Phase 3 trial, marking a significant setback for the company, which had high sales expectations for the vaccine prior to the failure amid ongoing pressures from Wall Street and the government.
- Moderna says key study of its CMV vaccine, expected to be its next big win, failed statnews.com
- Moderna scraps congenital virus program after vaccine shows little protective effect in phase 3 Fierce Biotech
- Moderna halts development of birth defect vaccine after trial setback Reuters
- Moderna Announces Phase 3 Study of Investigational Cytomegalovirus (CMV) Vaccine Did Not Meet Primary Efficacy Endpoint Yahoo Finance
- Moderna Drops Vaccine for Birth Defects After Trial Failure Barron's
Reading Insights
Total Reads
0
Unique Readers
1
Time Saved
1 min
vs 2 min read
Condensed
86%
270 → 39 words
Want the full story? Read the original article
Read on statnews.com